Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 20;60(7):4384-6.
doi: 10.1128/AAC.03098-15. Print 2016 Jul.

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

Tsukasa Ito-Horiyama  1 , Yoshikazu Ishii  2 , Akinobu Ito  1 , Takafumi Sato  3 , Rio Nakamura  1 , Norio Fukuhara  4 , Masakatsu Tsuji  1 , Yoshinori Yamano  1 , Keizo Yamaguchi  2 , Kazuhiro Tateda  2
Affiliations

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

Tsukasa Ito-Horiyama et al. Antimicrob Agents Chemother. .

Abstract

To better understand the antibacterial activity of S-649266 against carbapenemase producers, its stability against clinically relevant carbapenemases was investigated. The catalytic efficiencies (kcat/Km) of IMP-1, VIM-2, and L1 for S-649266 were 0.0048, 0.0050, and 0.024 μM(-1) s(-1), respectively, which were more than 260-fold lower than that for meropenem. Only slight hydrolysis of S-649266 against KPC-3 was observed. NDM-1 hydrolyzed meropenem 3-fold faster than S-649266 at 200 μM.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Chemical structure of S-649266.
See this image and copyright information in PMC

References

    1. Queenan AM, Bush K. 2007. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 20:440–458. doi:10.1128/CMR.00001-07. - DOI - PMC - PubMed
    1. Walsh TR. 2010. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 36(Suppl 3):S8–S14. doi:10.1016/S0924-8579(10)70004-2. - DOI - PubMed
    1. Nordmann P. 2014. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med Mal Infect 44:51–56. doi:10.1016/j.medmal.2013.11.007. - DOI - PubMed
    1. Tängdén T, Giske CG. 2015. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med 277:501–512. doi:10.1111/joim.12342. - DOI - PubMed
    1. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538–582. doi:10.1128/CMR.00058-07. - DOI - PMC - PubMed

MeSH terms